| pubmed-article:1670978 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:1670978 | lifeskim:mentions | umls-concept:C0020792 | lld:lifeskim |
| pubmed-article:1670978 | lifeskim:mentions | umls-concept:C0596981 | lld:lifeskim |
| pubmed-article:1670978 | lifeskim:mentions | umls-concept:C1704242 | lld:lifeskim |
| pubmed-article:1670978 | lifeskim:mentions | umls-concept:C0597357 | lld:lifeskim |
| pubmed-article:1670978 | lifeskim:mentions | umls-concept:C0034801 | lld:lifeskim |
| pubmed-article:1670978 | lifeskim:mentions | umls-concept:C1545588 | lld:lifeskim |
| pubmed-article:1670978 | pubmed:issue | 1 Pt 1 | lld:pubmed |
| pubmed-article:1670978 | pubmed:dateCreated | 1991-2-21 | lld:pubmed |
| pubmed-article:1670978 | pubmed:abstractText | Opioid receptors on isolated gastric smooth muscle cells were characterized pharmacologically by a technique in which synthetic selective opioid agonists and antagonists were used to protect and thus enrich a specific receptor type while all other receptors were inactivated by N-ethylamaleimide. Treatment of the cells with the selective mu-receptor agonist DAGO or antagonist CTAP preserved only the response to DAGO; treatment with the selective delta-receptor agonist DPDPE or antagonist naltrindole preserved only the response to DPPE; and treatment with the selective kappa-receptor agonist U50,488H or antagonist nor-binaltorphimine preserved only the response to U50,488H. The results established the presence of distinct kappa-, delta-, and mu-opioid receptors capable of mediating contraction of isolated gastric muscle cells. The pattern of interaction of endogenous opioid peptides with protected receptors implied that dynorphin-(1-13) and Met-enkephalin were selective agonists for kappa- and delta-opioid receptors, respectively, and Leu-enkephalin a preferential agonist of mu-opioid receptors. The results were confirmed by a reverse approach in which opioid receptors were inactivated by site-directed irreversible antagonists. beta-Funaltrexamine, a mu-selective antagonist, abolished the response to mu-receptor agonists, whereas beta-chlornaltrexamine, a mu- and kappa-selective antagonist, abolished the response to mu-receptor agonists and partially inhibited the response to kappa-receptor agonists. | lld:pubmed |
| pubmed-article:1670978 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1670978 | pubmed:language | eng | lld:pubmed |
| pubmed-article:1670978 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1670978 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:1670978 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1670978 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1670978 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1670978 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1670978 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1670978 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1670978 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1670978 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1670978 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1670978 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1670978 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1670978 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1670978 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1670978 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1670978 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1670978 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1670978 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:1670978 | pubmed:month | Jan | lld:pubmed |
| pubmed-article:1670978 | pubmed:issn | 0002-9513 | lld:pubmed |
| pubmed-article:1670978 | pubmed:author | pubmed-author:MakhloufG MGM | lld:pubmed |
| pubmed-article:1670978 | pubmed:author | pubmed-author:GriderJ RJR | lld:pubmed |
| pubmed-article:1670978 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:1670978 | pubmed:volume | 260 | lld:pubmed |
| pubmed-article:1670978 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:1670978 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:1670978 | pubmed:pagination | G103-7 | lld:pubmed |
| pubmed-article:1670978 | pubmed:dateRevised | 2007-11-14 | lld:pubmed |
| pubmed-article:1670978 | pubmed:meshHeading | pubmed-meshheading:1670978-... | lld:pubmed |
| pubmed-article:1670978 | pubmed:meshHeading | pubmed-meshheading:1670978-... | lld:pubmed |
| pubmed-article:1670978 | pubmed:meshHeading | pubmed-meshheading:1670978-... | lld:pubmed |
| pubmed-article:1670978 | pubmed:meshHeading | pubmed-meshheading:1670978-... | lld:pubmed |
| pubmed-article:1670978 | pubmed:meshHeading | pubmed-meshheading:1670978-... | lld:pubmed |
| pubmed-article:1670978 | pubmed:meshHeading | pubmed-meshheading:1670978-... | lld:pubmed |
| pubmed-article:1670978 | pubmed:meshHeading | pubmed-meshheading:1670978-... | lld:pubmed |
| pubmed-article:1670978 | pubmed:meshHeading | pubmed-meshheading:1670978-... | lld:pubmed |
| pubmed-article:1670978 | pubmed:meshHeading | pubmed-meshheading:1670978-... | lld:pubmed |
| pubmed-article:1670978 | pubmed:meshHeading | pubmed-meshheading:1670978-... | lld:pubmed |
| pubmed-article:1670978 | pubmed:meshHeading | pubmed-meshheading:1670978-... | lld:pubmed |
| pubmed-article:1670978 | pubmed:meshHeading | pubmed-meshheading:1670978-... | lld:pubmed |
| pubmed-article:1670978 | pubmed:meshHeading | pubmed-meshheading:1670978-... | lld:pubmed |
| pubmed-article:1670978 | pubmed:meshHeading | pubmed-meshheading:1670978-... | lld:pubmed |
| pubmed-article:1670978 | pubmed:meshHeading | pubmed-meshheading:1670978-... | lld:pubmed |
| pubmed-article:1670978 | pubmed:meshHeading | pubmed-meshheading:1670978-... | lld:pubmed |
| pubmed-article:1670978 | pubmed:meshHeading | pubmed-meshheading:1670978-... | lld:pubmed |
| pubmed-article:1670978 | pubmed:meshHeading | pubmed-meshheading:1670978-... | lld:pubmed |
| pubmed-article:1670978 | pubmed:meshHeading | pubmed-meshheading:1670978-... | lld:pubmed |
| pubmed-article:1670978 | pubmed:meshHeading | pubmed-meshheading:1670978-... | lld:pubmed |
| pubmed-article:1670978 | pubmed:year | 1991 | lld:pubmed |
| pubmed-article:1670978 | pubmed:articleTitle | Identification of opioid receptors on gastric muscle cells by selective receptor protection. | lld:pubmed |
| pubmed-article:1670978 | pubmed:affiliation | Department of Physiology, Medical College of Virginia, Richmond 23298-0711. | lld:pubmed |
| pubmed-article:1670978 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:1670978 | pubmed:publicationType | In Vitro | lld:pubmed |
| pubmed-article:1670978 | pubmed:publicationType | Research Support, U.S. Gov't, P.H.S. | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:1670978 | lld:pubmed |
